Main content

    Renal and Urinary Tract Cancer Clinical Trials

    CPMC Cancer ServicesOpens new window

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
    Description: Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects who have been diagnosed with transitional cell carcinoma of the urinary tract
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperP@cpmcri.org about Study CALGB 90601

    Title: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
    Description: Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects 18 y/o and older with confirmed renal cell carcinoma
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperP@cpmcri.org about Study SWOG S0931 (Everest)

    Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
    Description: Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)
    Investigators: David Minor, MD
    Eligibility: Subjects 18 y/o and older with confirmed renal cell carcinoma
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study ADAPT

    Title: Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma
    Description: Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery
    Eligibility: Subjects, 18 y/o and older, who have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperP@cpmcri.org about Study SWOG S1107

    • updated April 2014

    Back to top